Arcturus Therapeutics Ltd (ARCT) Stock Price, Quote & News

Company Profile

Arcturus Therapeutics Holdings Inc. engages in the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms includes LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate that is in phase 2 clinical trial for...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 900 2660

Website: arcturusrx.com

Address:

10285 Science Center Drive, San Diego, United States

JohnTrack Jan. 9 at 2:49 AM

$ARCT to Present at the 44th Annual J.P. Morgan Healthcare Conference https://www.rapidticker.com/news/arct-arcturus-therapeutics-to-present-at-a99a15

0 · Reply

bigchouse Jan. 8 at 11:33 PM

$ARCT Announce good news on Monday about ARCT-032 and payments from CSL? Do it for the shorts. Joseph Payne, President & Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, on Monday, January 12, 2026, at 5:15 p.m. Pacific Time.

0 · Reply

bigchouse Jan. 8 at 9:33 AM

$ARCT Severe flu season overwhelming Chicago area hospitals with more ER patients Kippenhan said his staff is seeing more people come to the hospital due to the flu, prompting concern. "When we're seeing numbers and positivity testing this high, this early, we're really worried that it's going to be an even more severe season," he said. Cook County officials said intensive care unit admissions for flu nearly doubled in the last week. https://www.cbsnews.com/chicago/news/severe-flu-season-hospitals-emergency-room-visits/

1 · Reply

wahoowa96 Jan. 8 at 5:52 AM

$ARCT Hey CSL apply for Australian commercialization of Kostsive. Why let Pfizer, Moderna and Novavax eat your lunch at your backyard and wimping about branching out CSL immunology group?

1 · Reply

wahoowa96 Jan. 8 at 5:46 AM

$ARCT You never know SA-mRNA Covid vaccine Kostsive sales in Europe could more than double the 4th quarter revenue of last year on top of workforce downsizing and stop on some vaccines developing programs. I honestly wish lime disease vaccine program was kept alive. Hopefully it's brought back to life after pipeline gets breathing room. Just curious why not CSL use Kostsive in Australia? As next commercialization target?

1 · Reply

Catbombs Jan. 7 at 9:47 PM

$ARCT

0 · Reply

bigchouse Jan. 7 at 7:25 AM

$ARCT I was wondering about the latest status of the 6 patients, who had taken 10mg dose of ARCT-032. Any more monitoring? Per Grok: Arcturus did not continue administering the 10mg dose of ARCT-032 beyond the initial 28-day treatment period for the six patients in the Phase 2 trial. The ongoing Phase 2 multiple ascending dose study (NCT06747858) involves separate cohorts receiving daily inhaled doses for 28 days: The second cohort consisted of six adults with Class I cystic fibrosis who received 10mg daily for 28 days. Interim data released in October 2025 showed the treatment was safe and well-tolerated, with early signs of biological activity (e.g., mucus plug reduction in 4/6 patients), but no meaningful improvement in lung function (FEV₁). There is no indication of extended or continued dosing at 10mg for those specific six patients beyond the protocol's 28 days. This is based on Arcturus' press releases and trial updates from October-November 2025.

3 · Reply

wahoowa95 Jan. 5 at 9:26 PM

$ARCT riding for CF today after all this rain. cant wait for the next powerball. #teamvertex

2 · Reply

Den00 Jan. 5 at 7:42 PM

$ARCT acording to Linkedin Juergen left the company....

3 · Reply

Newcar Jan. 5 at 1:10 PM

$ARCT It appears the vaccine isn't having commercial success where approved. Arcturus's only hope is CF therapy. If it fails again, it's game over...

1 · Reply

Arcturus Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 24, 2025, 4:01 PM EST - 6 weeks ago

Arcturus Therapeutics to Attend Upcoming Investor Conference

Nov 10, 2025, 9:01 PM EST - 2 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2025 Earnings Call Transcript

Nov 10, 2025, 4:01 PM EST - 2 months ago

Arcturus Therapeutics Announces Third Quarter 2025 Financial Update and Pipeline Progress

Nov 4, 2025, 4:01 PM EST - 2 months ago

Arcturus Therapeutics to Attend Upcoming Investor Conferences

Oct 28, 2025, 4:01 PM EDT - 2 months ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 10, 2025

Oct 22, 2025, 3:05 PM EDT - 2 months ago

Arcturus' Investigational Inhaled Therapy Lacks Meaningful Lung Function Improvement, Analyst Notes Mixed Picture

Oct 22, 2025, 8:53 AM EDT - 2 months ago

Arcturus Therapeutics shares plunge 56% after mixed phase 2 CF drug results

Oct 22, 2025, 7:30 AM EDT - 2 months ago

Arcturus Therapeutics Provides Interim Phase 2 Data for Cystic Fibrosis (CF) Program

Aug 11, 2025, 8:16 PM EDT - 5 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2025 Earnings Conference Call Transcript

Aug 11, 2025, 4:01 PM EDT - 5 months ago

Arcturus Therapeutics Announces Second Quarter 2025 Financial Update and Pipeline Progress

Jul 24, 2025, 4:01 PM EDT - 6 months ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 11, 2025

Jun 30, 2025, 11:00 AM EDT - 6 months ago

Arcturus Therapeutics Announces Positive Interim Phase 2 Multiple Dose Data for Ornithine Transcarbamylase (OTC) Deficiency Program

Jun 23, 2025, 8:30 AM EDT - 7 months ago

Arcturus Therapeutics to Host Key Opinion Leader (KOL) Presentation of ARCT-810 Phase 2 Interim Data for Ornithine Transcarbamylase (OTC) Deficiency

May 12, 2025, 7:40 PM EDT - 8 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q1 2025 Earnings Call Transcript

May 12, 2025, 4:01 PM EDT - 8 months ago

Arcturus Therapeutics Announces First Quarter 2025 Financial Update and Pipeline Progress

Apr 22, 2025, 4:01 PM EDT - 9 months ago

Arcturus Therapeutics to Report First Quarter Financial Results and Provide Corporate Update on May 12, 2025

Apr 10, 2025, 8:00 AM EDT - 9 months ago

Arcturus Therapeutics Receives U.S. FDA Fast Track Designation for the STARR® mRNA Vaccine Candidate ARCT-2304 for Pandemic Influenza A Virus H5N1

Mar 6, 2025, 9:44 PM EST - 11 months ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript

Mar 6, 2025, 4:01 PM EST - 11 months ago

Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress

Mar 5, 2025, 4:30 PM EST - 11 months ago

Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025

Feb 24, 2025, 4:01 PM EST - 11 months ago

Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025

Feb 14, 2025, 8:30 AM EST - 11 months ago

European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine

Feb 4, 2025, 8:30 AM EST - 1 year ago

Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate

Jan 31, 2025, 3:00 AM EST - 1 year ago

Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19

Jan 30, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference

Jan 10, 2025, 8:00 AM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial

Jan 6, 2025, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency

Dec 16, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Nov 18, 2024, 8:00 PM EST - 1 year ago

Arcturus Therapeutics to Present at Jefferies London Healthcare Conference

Nov 14, 2024, 1:44 PM EST - 1 year ago

Arcturus: LUNAR-CF For CF Presses On With 1st Half Of 2025 Interim Data

Nov 14, 2024, 1:00 AM EST - 1 year ago

Meiji Seika Pharma Announces Investment in ARCALIS, Inc.

Nov 11, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Receives Clearance from FDA to Begin H5N1 Pandemic Flu Vaccine Clinical Trial

Nov 7, 2024, 11:24 PM EST - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q3 2024 Earnings Call Transcript

Nov 7, 2024, 4:01 PM EST - 1 year ago

Arcturus Therapeutics Announces Third Quarter 2024 Financial Update and Pipeline Progress

Oct 31, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Report Third Quarter Financial Results and Provide Corporate Update on November 7, 2024

Sep 30, 2024, 8:00 AM EDT - 1 year ago

Self-Amplifying mRNA COVID-19 Vaccine Demonstrates Superior Immune Response Compared with mRNA Vaccine at 12 Months Post-Vaccination

Sep 13, 2024, 8:15 AM EDT - 1 year ago

Japan's Ministry of Health, Labor and Welfare Approves CSL and Arcturus Therapeutics' Updated Self-amplifying mRNA COVID-19 Vaccine for Protection against JN.1 Strain, to be Distributed in Japan by Meiji Seika Pharma

Sep 3, 2024, 8:30 AM EDT - 1 year ago

Arcturus Therapeutics Receives Clearance of an Investigational New Drug Application to U.S. Food and Drug Administration for ARCT-032, an Investigational Inhaled mRNA Therapeutic to Treat Cystic Fibrosis

Aug 27, 2024, 5:00 PM EDT - 1 year ago

Arcturus Therapeutics to Attend Upcoming Investor & Scientific Conferences

Aug 9, 2024, 5:27 AM EDT - 1 year ago

High-Risk, High-Reward: Arcturus Nears Commercialization Of Kostaive Vaccine

Aug 5, 2024, 8:50 PM EDT - 1 year ago

Arcturus Therapeutics Holdings Inc. (ARCT) Q2 2024 Earnings Call Transcript

Aug 5, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Announces Second Quarter 2024 Financial Update and Pipeline Progress

Aug 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference

Jul 18, 2024, 7:30 PM EDT - 1 year ago

Arcturus Therapeutics to Report Second Quarter Financial Results and Provide Corporate Update on August 5, 2024

Jul 1, 2024, 4:01 PM EDT - 1 year ago

Arcturus Therapeutics Provides Updates for Ornithine Transcarbamylase (OTC) Deficiency and Cystic Fibrosis (CF) Programs

Jun 20, 2024, 8:00 AM EDT - 1 year ago

Arcturus Therapeutics Appoints Moncef Slaoui, Ph.D., to Board of Directors

Jun 8, 2024, 2:42 AM EDT - 1 year ago

Arcturus: A Hidden Gem In The Biotech Sector

Jun 7, 2024, 10:30 AM EDT - 1 year ago

Arcturus Therapeutics Presents New Clinical Data at 47th Annual European Cystic Fibrosis Conference

JohnTrack Jan. 9 at 2:49 AM

$ARCT to Present at the 44th Annual J.P. Morgan Healthcare Conference https://www.rapidticker.com/news/arct-arcturus-therapeutics-to-present-at-a99a15

0 · Reply

bigchouse Jan. 8 at 11:33 PM

0 · Reply

bigchouse Jan. 8 at 9:33 AM

1 · Reply

wahoowa96 Jan. 8 at 5:52 AM

$ARCT Hey CSL apply for Australian commercialization of Kostsive. Why let Pfizer, Moderna and Novavax eat your lunch at your backyard and wimping about branching out CSL immunology group?

1 · Reply

wahoowa96 Jan. 8 at 5:46 AM

1 · Reply

Catbombs Jan. 7 at 9:47 PM

$ARCT

0 · Reply

bigchouse Jan. 7 at 7:25 AM

3 · Reply

wahoowa95 Jan. 5 at 9:26 PM

$ARCT riding for CF today after all this rain. cant wait for the next powerball. #teamvertex

2 · Reply

Den00 Jan. 5 at 7:42 PM

$ARCT acording to Linkedin Juergen left the company....

3 · Reply

Newcar Jan. 5 at 1:10 PM

$ARCT It appears the vaccine isn't having commercial success where approved. Arcturus's only hope is CF therapy. If it fails again, it's game over...

1 · Reply

bigchouse Jan. 4 at 6:04 PM

$ARCT Yes, growth initiatives that generate strong returns can effectively offset ATM dilution. Key initiatives include: Funding R&D that leads to new products or breakthroughs (common in biotech and tech) Strategic acquisitions that enhance revenue or market share Expanding production capacity to meet rising demand Paying down high-cost debt, improving net income and EPS Scaling operations to achieve profitability faster When the capital from an ATM is deployed into initiatives that grow earnings faster than shares increase, EPS rises, counteracting dilution and supporting the stock price.

0 · Reply

wahoowa95 Jan. 3 at 10:50 PM

$ARCT With the announcement of Kostaive being approved in the UK I expect this stock to drop 50% and be at $3 on Monday

2 · Reply

bigchouse Jan. 3 at 2:07 AM

$ARCT

1 · Reply

bigchouse Jan. 2 at 9:25 PM

$ARCT Per Grok: Yes, the MHRA approval of zapomeran (Kostaive) is expected to trigger a milestone payment to Arcturus Therapeutics from its partner CSL Seqirus. The exact amount of the milestone payment triggered by the MHRA approval of zapomeran (Kostaive) has not been publicly disclosed.

0 · Reply

King316 Jan. 2 at 4:44 PM

$ARCT https://www.gov.uk/government/news/mhra-approves-zapomeran-kostaive-mrna-covid-19-vaccine

1 · Reply

Den00 Jan. 2 at 3:53 PM

$ARCT preparations for capital raise has start (Base Prospectus, ATM Prospectus)

1 · Reply

Nganlm Jan. 2 at 3:41 PM

$ARCT UK'S MHRA: APPROVED ZAPOMERAN (KOSTAIVE) MRNA COVID-19 VACCINE, FOR IMMUNISATION OF INDIVIDUALS AGED 18 YEARS AND OLDER The above news read from Reuters…

2 · Reply

wahoowa96 Jan. 2 at 1:01 AM

$ARCT To me LNP was worth around $1B for Capstan tLNP technology. I would ask the court to make Capstan return/pay $1B to Arcturus and lower Capstan therapeutics buyout by $1B from AbbVie. Then I am in ✌️.

1 · Reply

wahoowa96 Jan. 2 at 12:53 AM

$ARCT AbbVie is paying $2.1B for LNP and the tricks to couple a specific antibody to T-cell for car-T reprogramming in auto-immune disease treatment with mRNA delivered to T-cell (I think you can use third-party service for this Ab coupling if it's not existing in-house). The thing is LNP delivery of mRNA therapeutics was not there in 2021 at Capstan till the arrival of ex-Arcturus employees. Then all of sudden Capstan filed for an patent protection on antibody conjugated LNP based mRNA delivery method in 2021 around arrival if Arcturus ex-employees.

1 · Reply

wahoowa96 Jan. 1 at 4:55 PM

$ARCT Happy New Year!

0 · Reply

bigchouse Jan. 1 at 10:18 AM

$ARCT Ok, I found the information. Plaintiff shall respond to Defendants' motion to dismiss (ECF No.21 ) by no later than January 22, 2026. Defendants may file a reply on or before February 12, 2026.

1 · Reply

bigchouse Jan. 1 at 10:11 AM

$ARCT Aren't we suppose to hear an update on January 6th for this case? Arcturus Therapeutics, Inc. v. AbbVie Inc. et al (Case No. 3:25-cv-02494) Arcturus alleges that former employees and a consultant misappropriated trade secrets related to its proprietary lipid nanoparticle (LNP) drug-delivery technology. These individuals joined Capstan Therapeutics, which allegedly used the secrets to develop competing technology and file patents. AbbVie acquired Capstan in a deal worth up to $2.1 billion (announced earlier in 2025 and completed around August), and Arcturus claims much of Capstan's value derived from the stolen trade secrets. Arcturus is seeking monetary damages and an injunction to prevent AbbVie from using the alleged trade secrets.

1 · Reply

Market Cap	194.35M
Revenue (ttm)	152.31M
Net Income (ttm)	-80.94M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-53.14%
Debt to Equity Ratio	0.00

Volume	444,900
Avg Vol	840,594
Day's Range	N/A - N/A
Shares Out	28.41M
Stochastic %K	77%
Beta	2.24
Analysts	Strong Sell
Price Target	$34.14